礼来与 Hims & Hers扩大获得 FDA批准的礼来药物的渠道-动脉网

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

CISION 等信源发布 2026-11-06 19:47



可切换为仅中文







Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform

该协议通过 Hims & Hers 平台，为患者提供以自费价格获得 FDA 批准治疗方案的途径

INDIANAPOLIS

印第安纳波利斯

，

Nov. 6, 2026

2026年11月6日

/PRNewswire/ -- Eli Lilly and Company (NYSE:

/美通社/ -- 礼来公司（纽约证券交易所：

LLY

礼来公司

) and Hims & Hers Health, Inc. (NYSE:

）以及 Hims & Hers Health, Inc.（纽约证券交易所：

HIMS

) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform..

）今日宣布达成协议，以帮助扩大Zepbound（替尔泊肽）和Foundayo（orforglipron）的可及性。根据该协议，在Hims & Hers平台上从持证医疗提供者处获得处方的符合条件的患者，无需离开该平台，即可享受与其他任何患者相同的自费价格。

The agreement brings together Lilly's obesity medicines and Hims & Hers' consumer platform. Patients can complete a consultation, receive a prescription if their provider determines it is appropriate, and have an FDA-approved Lilly medicine shipped directly to their home, all in one seamless experience.

该协议将礼来的肥胖症药物与 Hims & Hers 的消费者平台相结合。患者可以在一次无缝体验中完成问诊，若医疗服务提供者判定适用，则可获得处方，并由礼来直接配送 FDA 批准的药物至家中。

Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound..

自费价格方面，Foundayo 每月起价为 149 美元，Zepbound 每月起价为 299 美元。

'At Lilly, we are always looking for new ways to help more people get the medicines they need, and that means meeting patients where they already are,' said Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities, Eli Lilly and Company. 'Millions of people turn to Hims & Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed.'.

“在礼来，我们始终在探索新的方式，以帮助更多患者获得他们所需的药物，这意味着要在患者 already 所处的场景中为他们提供服务，”礼来公司美国及全球客户能力执行副总裁兼总裁伊利亚·尤法表示。“数百万人选择 Hims & Hers 作为其医疗保健服务提供方，而通过此项协议，这些患者在获得处方的情况下，现在能够以更简便、更直接的方式，以可负担的价格获取经美国食品药品监督管理局（FDA）批准的礼来药物。”

Adults with obesity have shown strong and growing interest in getting care, including prescription medicines, through telehealth providers, especially as a broader range of FDA-approved

肥胖成年人对通过远程医疗提供者获得护理（包括处方药）表现出强烈且日益增长的兴趣，尤其是随着更广泛的FDA批准

GLP-1

胰高血糖素样肽-1

treatments—including Lilly's daily oral medicine, Foundayo—have become available. This agreement between Lilly and Hims & Hers helps expand access to patients who choose to seek care through one of the largest digital health platforms in the world.

包括礼来公司的每日口服药物Foundayo在内的治疗方案已问世。礼来公司与Hims & Hers达成的这项协议，有助于扩大那些选择通过全球最大数字健康平台之一寻求护理的患者的用药可及性。

'Lilly is one of the most innovative pharmaceutical companies in history, and I'm incredibly proud that Hims & Hers is a part of making sure more people can access the medicines they've created,' said Andrew Dudum, co-founder and CEO of Hims & Hers. 'By working together, we're not just reaching more people with obesity with seamless, personal access to FDA-approved Lilly medicine.

“礼来是历史上最具创新精神的制药公司之一，我感到无比自豪的是，Hims & Hers 正参与其中，确保更多人能够获得他们研发的药物，”Hims & Hers 联合创始人兼首席执行官安德鲁·杜杜姆表示。“通过携手合作，我们不仅让更多肥胖症患者能够便捷、个性化地获得美国食品药品监督管理局批准的礼来药物。”

We're showing the industry what innovators can achieve for customers everywhere when we work together to make the world well.'.

我们正在向业界展示，当我们携手共创美好世界时，创新者能够为全球客户带来怎样的成就。

Hims & Hers supports customers through their entire health journey, from their very first question to their clinical treatment and continued follow-up care. Its technology platform supports provider outreach, follow-up care, and treatment planning. Weight loss patients on Hims & Hers receive a membership experience that includes 24/7 access to a care team, nutrition guidance, regular clinical check-ins, and access to the Hims & Hers Weight Loss community..

Hims & Hers 在客户的整个健康旅程中提供支持，从最初的健康咨询到临床治疗及持续的随访护理。其技术平台支持医生联络、随访护理和治疗规划。Hims & Hers 的减重患者可享受会员服务体验，包括全天候访问护理团队、营养指导、定期临床随访以及加入 Hims & Hers 减重社区。

Hims & Hers has never offered access to compounded copies of Lilly's GLP-1s, and has committed not to do so in the future. Additionally, as part of the agreement, the companies have committed to protecting independent clinical decision-making, so that providers on the Hims & Hers platform continue to prescribe the treatment they determine is right for each patient..

Hims & Hers 从未提供过礼来公司 GLP-1 药物的复合仿制版 access，并承诺将来也不会这样做。此外，作为协议的一部分，两家公司承诺保护独立的临床决策权，以便 Hims & Hers 平台上的医疗服务提供者能够继续为患者开具其认为最适合的治疗方案。

About Lilly

关于礼来

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.

礼来是一家将科学转化为疗愈、致力于改善全球人民生活的医药公司。近150年来，我们一直引领着改变生命的发现，如今我们的药物帮助了全球数千万人。凭借生物技术、化学和基因医学的力量，我们的科学家正迫切推进新发现，以应对一些全球最重大的健康挑战：重新定义糖尿病护理；治疗肥胖并遏制其最具破坏性的长期影响；推进对抗阿尔茨海默病的斗争；为一些最使人衰弱的免疫系统疾病提供解决方案；并将最难治疗的癌症转化为可管理的疾病。

With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit .

在迈向更健康世界的每一步中，我们始终受一个目标驱动：让数百万人的生活变得更加美好。这包括开展反映世界多样性的创新临床试验，并致力于确保我们的药物可及且负担得起。欲了解更多信息，请访问。

Lilly.com

礼来公司官网

and

和

Lilly.com/news

礼来官网新闻

, or follow us on

，或在上关注我们

Facebook

，

Instagram

, and

，和

领英

. C-LLY

C-LLY

About Hims & Hers

关于 Hims & Hers

Hims & Hers is a leading global health and wellness platform on a mission to help the world feel great through the power of better health. Hims & Hers connects consumers to licensed healthcare professionals, enabling them to access personalized treatments for conditions related to weight loss, mental health, sexual health, dermatology and more.

Hims & Hers 是全球领先的健康与 wellness 平台，致力于通过更优质的健康力量帮助世人焕发活力。Hims & Hers 将消费者与持证医疗专业人士相连接，使其能够获得针对减肥、心理健康、性健康、皮肤科等相关疾病的个性化治疗方案。

For more information, visit .

更多信息，请访问。

www.himsandhershealth.com

。

ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS

ZEPBOUND 适应症与安全概要（含警告）

Zepbound

泽邦德

(ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:

(ZEHP-bownd) 是一种注射处方药，配合低热量饮食和增加体力活动，用于帮助成年人：

obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

肥胖症，或一些伴有体重相关医学问题的超重成年人，以减轻多余体重并维持减重效果。

moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.

中重度阻塞性睡眠呼吸暂停（OSA）和肥胖，以改善其OSA。

Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any

Zepbound 含有替尔泊肽，不应与其他含替尔泊肽的产品或任何

GLP-1

胰高血糖素样肽-1

receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

受体激动剂类药物。目前尚不清楚Zepbound在儿童中的安全性和有效性。

Warnings

警告

- Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

- Zepbound 可能导致甲状腺肿瘤，包括甲状腺癌。请留意可能的症状，如颈部肿块或肿胀、声音嘶哑、吞咽困难或呼吸急促。如果出现任何上述症状，请告知您的医疗保健提供者。

Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).

如果您或您的家人曾患有称为甲状腺髓样癌（MTC）的甲状腺癌，请勿使用Zepbound。

Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

如果您患有2型多发性内分泌腺瘤病（MEN 2），请勿使用Zepbound。

Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.

如果您曾对替尔泊肽或Zepbound中的任何成分发生严重过敏反应，请勿使用Zepbound。

KwikPen

: Do not share your KwikPen with other people, even if the pen needle has been changed.

：不要与他人共用您的 KwikPen，即使已更换笔针。

You may give other people a serious infection or get a serious infection from them.

你可能会将严重感染传染给他人，或者从他人那里感染严重疾病。

Zepbound may cause serious side effects, including:

Zepbound 可能引起严重的副作用，包括：

Severe stomach problems.

严重的胃部问题。

Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

据报道，使用Zepbound的人群中曾出现胃部问题，有时较为严重。如果您出现严重或持续不退的胃部问题，请告知您的医疗保健提供者。

Dehydration leading to kidney problems.

脱水导致肾脏问题。

Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

腹泻、恶心和呕吐可能导致体液流失（脱水），从而引发肾脏问题。补充水分对于降低脱水风险至关重要。如果出现持续不缓解的恶心、呕吐或腹泻，请立即告知您的医疗保健提供者。

Gallbladder problems.

胆囊问题。

Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

部分使用 Zepbound 的患者出现了胆囊问题。如果您出现胆囊问题的症状，包括上腹部（腹部）疼痛、发热、皮肤或眼睛发黄（黄疸）或陶土色粪便，请立即告知您的医疗保健提供者。

Inflammation of the pancreas (pancreatitis).

胰腺炎症（胰腺炎）。

Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back.

如果您出现持续不缓解的严重腹痛（腹部疼痛），无论是否伴有恶心或呕吐，请立即停用 Zepbound 并马上联系您的医疗保健提供者。您可能会感到疼痛从腹部放射至背部。

Serious allergic reactions.

严重过敏反应。

Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

如果您出现任何严重过敏反应的症状，包括面部、嘴唇、舌头或喉咙肿胀，呼吸或吞咽困难，严重皮疹或瘙痒，晕厥或头晕，或心跳过快，请立即停用 Zepbound 并寻求医疗帮助。

Low blood sugar (hypoglycemia).

低血糖（低血糖症）。

Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin.

如果您将Zepbound与可能导致低血糖的药物（如磺酰脲类或胰岛素）一起使用，您出现低血糖的风险可能会更高。

Signs and symptoms of low blood sugar

低血糖的体征和症状

may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

可能包括头晕或头昏、出汗、意识模糊或嗜睡、头痛、视力模糊、言语不清、颤抖、心跳加快、焦虑、易怒、情绪变化、饥饿感、虚弱或感到坐立不安。

Changes in vision in patients with type 2 diabetes.

2型糖尿病患者视力变化。

Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

如果您在使用 Zepbound 治疗期间出现视力变化，请告知您的医疗保健提供者。

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).

在手术或其他使用麻醉或深度镇静（深睡状态）的操作过程中，食物或液体进入肺部。

Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Zepbound 可能会增加在手术或其他操作过程中食物进入肺部的风险。在安排手术或其他操作之前，请告知所有您的医疗保健提供者您正在使用 Zepbound。

Common side effects

常见副作用

The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss

Zepbound 最常见的副作用包括恶心、腹泻、呕吐、便秘、胃痛（腹痛）、消化不良、注射部位反应、疲劳感、过敏反应、嗳气和脱发。

，

and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

以及烧心。这些并非 Zepbound 所有可能的副作用。如有任何令您困扰或持续不退的副作用，请咨询您的医疗保健提供者。

Tell your doctor if you have any side effects.

如有任何副作用，请告知您的医生。

You can report side effects at 1-800-FDA-1088 or

您可以通过 1-800-FDA-1088 报告副作用，或

www.fda.gov/medwatch

。

Before using Zepbound

使用 Zepbound 之前

Your healthcare provider should show you how to use Zepbound before you use it for the first time.

在您首次使用 Zepbound 之前，您的医疗保健提供者应向您展示如何正确使用该药物。

Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.

与您的医疗保健提供者讨论低血糖问题及其管理方法。如果您正在服用治疗糖尿病的药物，包括胰岛素或磺酰脲类药物，请告知您的医疗保健提供者。

If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound.

如果您口服避孕药，请在使用 Zepbound 之前咨询您的医疗保健提供者。在使用 Zepbound 期间，避孕药的效果可能会降低。

Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound.

您的医疗保健提供者可能会建议您在开始使用 Zepbound 后的 4 周内，以及在每次增加 Zepbound 剂量后的 4 周内，采用另一种类型的避孕措施。

Review these questions with your healthcare provider:

与您的医疗保健提供者一起审阅以下问题：

❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?

❑ 您是否有其他疾病，包括胰腺问题，或严重的胃部问题，例如胃排空延迟（胃轻瘫）或食物消化问题？

❑ Do you take diabetes medicines, such as insulin or sulfonylureas?

❑ 您是否服用糖尿病药物，例如胰岛素或磺酰脲类药物？

❑ Do you have a history of diabetic retinopathy?

❑ 您是否有糖尿病视网膜病变病史？

❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?

❑ 您是否已安排进行需要使用麻醉或深度镇静（深度睡眠状态）的手术或其他操作？

❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?

❑ 您是否正在服用其他处方药、非处方药、维生素或草本补充剂？

❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound..

❑ 您是否怀孕、计划怀孕、正在哺乳或计划哺乳？Zepbound 可能对您的未出生婴儿造成伤害。如果您在使用 Zepbound 期间怀孕，请告知您的医疗保健提供者。Zepbound 可能进入您的母乳中。您应与医疗保健提供者讨论在使用 Zepbound 期间喂养婴儿的最佳方式。

Pregnancy Exposure Registry:

妊娠暴露登记处：

There is a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may call 1-844-524-0039 or email at .

有一个针对在怀孕期间使用过Zepbound的女性的妊娠暴露登记系统。该登记系统的目的是收集有关您和宝宝健康状况的信息。请与您的医疗保健提供者讨论如何参与此登记系统，或者您可以拨打1-844-524-0039或通过电子邮件联系。

MILEregistry@thermofisher.com

or visit

或访问

https://pregnancyregistry.lilly.com/zepbound

。

How to take

服用方法

Read the Instructions for Use that come with Zepbound.

阅读随 Zepbound 附带的说明书。

Use Zepbound exactly as your healthcare provider says.

请严格按照您的医疗保健提供者的指示使用Zepbound。

Use Zepbound with a reduced-calorie diet and increased physical activity.

使用 Zepbound 时应配合低热量饮食并增加体力活动。

Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or have another person inject in the back of the upper arm.

将 Zepbound 注射于腹部（肚子）、大腿的皮下，或由他人注射于上臂后侧的皮下。

Do not

不要

inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously).

将ZEPBOUND注射到肌肉（肌肉注射）或静脉（静脉注射）。

Use Zepbound 1 time each week, at any time of the day.

每周使用一次 Zepbound，一天中的任何时间均可。

Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection.

每次每周注射时更换（轮换）注射部位。不要每次注射都使用同一部位。

If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

如果您服用了过量的 Zepbound，请立即联系您的医疗保健提供者、拨打中毒帮助热线 1-800-222-1222，或前往最近的医院急诊室。

Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.

Zepbound 获批的注射剂规格为 2.5 mg、5 mg、7.5 mg、10 mg、12.5 mg 和 15 mg。

Learn more

了解更多

Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to

Zepbound 是一种处方药。欲了解更多信息，请致电 1-800-LillyRx（1-800-545-5979）或访问

www.zepbound.lilly.com

。

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it.

本摘要提供有关 Zepbound 的基本信息，但并未涵盖该药品的所有已知信息。每次配药时，请阅读随处方附带的信息。这些信息不能替代与您的医疗保健提供者的沟通。请务必就 Zepbound 及其服用方法咨询您的医疗保健提供者。

Your healthcare provider is the best person to help you decide if Zepbound is right for you..

您的医疗保健提供者是帮助您决定 Zepbound 是否适合您的最佳人选。

ZP CON BS 01SEP2026

ZP CON BS 2026年9月1日

FOUNDAYO INDICATION AND SAFETY SUMMARY WITH WARNINGS

FOUNDAYO 适应症与安全性概要（含警告）

Foundayo (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

Foundayo（发音：fown-DAY-oh）是一种处方药，配合低热量饮食和增加体力活动，用于帮助肥胖症成人，或伴有体重相关医学问题的部分超重成人，减轻多余体重并维持减重效果。

Foundayo should not be used with other

Foundayo 不应与其他

GLP-1

receptor agonist medicines.

受体激动剂药物。

It is not known if Foundayo is safe and effective for use in children.

尚不清楚 Foundayo 在儿童中使用的安全性和有效性。

Warnings –

警告 –

Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Foundayo 可能导致甲状腺肿瘤，包括甲状腺癌。请留意可能的症状，如颈部肿块或肿胀、声音嘶哑、吞咽困难或呼吸短促。如果出现任何上述症状，请告知您的医疗保健提供者。

Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).

如果您或您的任何家庭成员曾患有称为髓样甲状腺癌（MTC）的甲状腺癌，请勿使用 Foundayo。

Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

如果您患有多发性内分泌腺瘤病2型（MEN 2），请勿使用Foundayo。

Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo.

如果您对 orforglipron 或 Foundayo 中的任何成分曾发生严重过敏反应，请勿使用 Foundayo。

Foundayo may cause serious side effects, including:

Foundayo 可能导致严重的副作用，包括：

Inflammation of the pancreas (pancreatitis).

胰腺炎。

Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

如果您出现持续不缓解的严重腹痛（腹部疼痛），无论是否伴有恶心或呕吐，请立即停止服用 Foundayo 并马上联系您的医疗保健提供者。有时，您可能会感到腹痛放射至背部。

Severe stomach problems.

严重的胃部问题。

Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

使用 Foundayo 的患者中曾有胃部问题的报告，有时可能较为严重。如果您出现严重或持续不缓解的胃部问题，请告知您的医疗保健提供者。

Dehydration leading to kidney problems.

脱水导致肾脏问题。

Low blood sugar (hypoglycemia).

低血糖（低血糖症）。

Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery..

如果您将 Foundayo 与可能导致低血糖的药物（如胰岛素或磺酰脲类药物）联合使用，您发生低血糖的风险可能会更高。低血糖的体征和症状可能包括头晕或头重脚轻、出汗、意识模糊或嗜睡、头痛、视力模糊、言语不清、颤抖、心跳加快、焦虑、易怒、情绪变化、饥饿感、无力或感到心神不宁。

Serious allergic reactions.

严重过敏反应。

Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

如果您出现任何严重过敏反应的症状，包括面部、嘴唇、舌头或喉咙肿胀，呼吸或吞咽困难，严重皮疹或瘙痒，昏厥或头晕，或心跳极快，请立即停止使用 Foundayo 并寻求医疗帮助。

Changes in vision in patients with type 2 diabetes.

2型糖尿病患者的视力变化

Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

如果您在使用 Foundayo 治疗期间出现视力变化，请告知您的医疗保健提供者。

Gallbladder problems.

胆囊问题。

Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

部分使用 Foundayo 的患者曾出现胆囊问题。如果您出现胆囊问题的症状，包括上腹部（腹部）疼痛、发热、皮肤或眼睛发黄（黄疸）或陶土色粪便，请立即告知您的医疗保健提供者。

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).

在手术或其他使用麻醉或深度镇静（深度嗜睡）的操作过程中，食物或液体进入肺部。

Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

服用 Foundayo 可能会增加在手术或其他操作过程中食物误吸入肺部的风险。在计划进行手术或其他操作前，请告知您的医疗保健提供者您正在服用 Foundayo。

Common side effects

常见副作用

The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away..

Foundayo 最常见的副作用包括恶心、便秘、腹泻、呕吐、消化不良、胃（腹部）疼痛、头痛、腹部肿胀、疲劳感、嗳气、烧心、胀气和脱发。这些并非 Foundayo 所有可能的副作用。如有任何令您困扰或持续不退的副作用，请咨询您的医疗保健提供者。

Tell your doctor if you have any side effects.

如果您出现任何副作用，请告知您的医生。

You can report side effects at 1-800-FDA-1088 or

您可以通过 1-800-FDA-1088 报告副作用，或

www.fda.gov/medwatch

。

Before taking Foundayo

在服用 Foundayo 之前

Tell your healthcare provider about all the medicines you take.

告知您的医疗保健提供者您正在服用的所有药物。

Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works.

Foundayo 可能会影响某些药物的作用方式，而某些药物也可能会影响 Foundayo 的作用方式。

Pregnancy Exposure Registry:

妊娠暴露登记处：

There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979). .

将设立一个妊娠暴露登记系统，用于记录在妊娠期间服用 Foundayo 的女性。该登记系统的目的是收集有关您和宝宝健康状况的信息。请与您的医疗保健提供者沟通，了解如何参与该登记系统，或者您可以联系礼来公司（Eli Lilly and Company），电话：1-800-LillyRx（1-800-545-5979）。

If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo.

如果您正在口服避孕药，请在服用 Foundayo 之前咨询您的医疗保健提供者。在服用 Foundayo 期间，避孕药的疗效可能会降低。

Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo.

您的医疗保健提供者可能会建议在开始使用 Foundayo 后的 30 天内，以及每次增加 Foundayo 剂量后的 30 天内，采用另一种避孕方式。

Talk to your healthcare provider about low blood sugar and how to manage it.

与您的医疗保健提供者讨论低血糖问题及其管理方法。

Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.

如果您正在使用包括胰岛素或磺脲类药物在内的糖尿病治疗药物，请告知您的医疗保健提供者。

Review these questions with your healthcare provider:

与您的医疗保健提供者一起审查这些问题：

❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?

❑ 您是否有其他疾病，包括胰腺或肾脏问题，或严重的肝脏问题、严重的胃部问题（如胃排空延迟[胃轻瘫]或食物消化障碍）？

❑ Do you have a history of diabetic retinopathy?

❑ 您是否有糖尿病视网膜病变病史？

❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?

❑ 您是否已安排进行需要使用麻醉或深度镇静（深睡状态）的手术或其他操作？

❑ Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.

❑ 您是否怀孕或计划怀孕？Foundayo 可能会对您的胎儿造成伤害。

❑ Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.

❑ 您是否正在哺乳或计划哺乳？在 Foundayo 治疗期间，不建议进行母乳喂养。

❑ Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?

❑ 您是否正在服用其他处方药、非处方药、维生素或草本补充剂？

How to take

服用方法

Take Foundayo exactly as your healthcare provider tells you to.

请严格遵照医疗保健提供者的指示使用 Foundayo。

Use Foundayo with a reduced-calorie diet and increased physical activity.

配合低热量饮食和增加体力活动使用 Foundayo。

Take Foundayo by mouth 1 time each day, with or without food.

每日口服一次 Foundayo，可与食物同服或空腹服用。

Swallow tablets whole. Do not break, crush, or chew the tablet.

整片吞服。请勿掰开、压碎或咀嚼药片。

If you miss a dose, take it as soon as possible.

如果漏服一剂，请尽快补服。

Do not

不要

take

拿

doses of Foundayo in the same day.

同日服用 Foundayo 的剂量。

Do not take more than 1 tablet per day.

每日服用不得超过1片。

If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment.

如果您连续7天或更长时间漏服Foundayo，请联系您的医疗保健提供者，讨论如何重新开始治疗。

If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

如果您服用了过量的 Foundayo，请立即联系您的医疗保健提供者或拨打中毒帮助热线 1-800-222-1222，或前往最近的医院急诊室。

Learn more

了解更多

Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to

Foundayo 是一种处方药，有 0.8 mg、2.5 mg、5.5 mg、9 mg、14.5 mg 或 17.2 mg 的口服片剂。如需更多信息，请致电 1-800-545-5979 或访问

foundayo.lilly.com

。

This summary provides basic information about Foundayo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Foundayo and how to take it.

本摘要提供关于 Foundayo 的基本信息，但并未包含该药品的所有已知信息。每次配药时，请阅读随处方附带的说明。本信息不能替代与医生的沟通。请务必就 Foundayo 及其服用方法咨询您的医生或其他医疗保健提供者。

Your doctor is the best person to help you decide if Foundayo is right for you..

您的医生是帮助您判断 Foundayo 是否适合您的最佳人选。

OG CON BS APR2026

OG CON BS 2026年4月

Foundayo

™

商标

is a trademark of Eli Lilly and Company.

是礼来公司的商标。

Lilly Cautionary Statement Regarding Forward-Looking Statements

礼来公司关于前瞻性陈述的警示性声明

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about an agreement between Lilly and Hims & Hers to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron) to eligible patients who receive a prescription from a licensed provider via the Hims & Hers platform and reflects Lilly's current beliefs and expectations.

本新闻稿包含涉及礼来公司与 Hims & Hers 之间一项协议的前瞻性陈述（该术语定义见1995年《私人证券诉讼改革法》），旨在帮助扩大符合条件的患者通过 Hims & Hers 平台从持证医疗提供者处获得处方后使用 Zepbound（替尔泊肽）和 Foundayo（orforglipron）的机会，并反映了礼来公司当前的信念和预期。

However, there can be no assurance that the agreement will be implemented as anticipated, that the parties will realize its expected benefits, or that Lilly will execute its strategy as planned. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission.

然而，无法保证该协议将按预期实施，各方将实现其预期收益，或礼来公司将按计划执行其战略。有关可能导致实际结果与礼来公司预期不符的、与礼来公司业务相关的风险和不确定性的进一步讨论，请参阅礼来公司向美国证券交易委员会提交的10-K表和10-Q表文件。

Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release..

除法律要求外，礼来公司不承担更新前瞻性陈述以反映本新闻稿发布日后发生的事件的义务。

Hims & Hers Cautionary Statement Regarding Forward-Looking Statements

Hims & Hers 关于前瞻性陈述的警示性声明

Cautionary Note Regarding Forward-Looking Statements:

关于前瞻性陈述的警示性说明：

This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believes,' 'estimates,' 'anticipates,' 'expects,' 'intends,' 'plans,' 'assume,' 'may,' 'will,' 'likely,' 'potential,' 'projects,' 'predicts,' 'continue,' 'goal,' 'strategy,' 'future,' 'forecast,' 'target,' 'outlook,' 'opportunity,' 'project,' 'confidence,' 'foundation,' 'groundwork,' or 'should,' or, in each case, their negative or other variations or comparable terminology.

本通讯包含经修订的《1933年证券法》第27A条和经修订的《1934年证券交易法》第21E条所定义的“前瞻性陈述”。这些前瞻性陈述可以通过使用前瞻性术语来识别，包括但不限于“相信”、“估计”、“预期”、“期望”、“打算”、“计划”、“假设”、“可能”、“将”、“很可能”、“潜在”、“规划”、“预测”、“继续”、“目标”、“战略”、“未来”、“预测”、“指标”、“展望”、“机会”、“项目”、“信心”、“基础”、“铺垫”或“应当”，或在各种情况下，其否定形式、其他变体或类似术语。

There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding the agreement between Eli Lilly and Company and Hims & Hers, including the availability of Zepbound (tirzepatide) and Foundayo (orforglipron) on the Hims & Hers platform, related self-pay pricing, and the potential effects of the agreement on customers and Hims & Hers' business.

无法保证实际结果不会与预期存在重大差异。此类陈述包括但不限于关于礼来公司（Eli Lilly and Company）与 Hims & Hers 之间协议的陈述，包括 Zepbound（替尔泊肽）和 Foundayo（orforglipron）在 Hims & Hers 平台上的供应情况、相关的自费定价，以及该协议对客户及 Hims & Hers 业务的潜在影响。

These statements are based on management's current expectations, but actual results may differ materially due to various factors..

这些陈述基于管理层当前的预期，但由于各种因素，实际结果可能会有重大差异。

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on Hims & Hers' current expectations, assumptions and beliefs concerning future developments and their potential effects on us.

前瞻性陈述既非历史事实，亦非对未来表现的保证。相反，本沟通文件中所载的前瞻性陈述基于 Hims & Hers 对未来发展及其对我们潜在影响的当前预期、假设和信念。

Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Hims & Hers' control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.

影响我们的未来发展可能并非我们所预期。这些前瞻性陈述涉及多种风险、不确定性（其中部分超出 Hims & Hers 的控制范围）以及其他假设，可能导致实际结果或表现与这些前瞻性陈述所明示或暗示的内容存在重大差异。

These risks and uncertainties include, but are not limited to, the timing and logistical considerations related to the integration and rollout of Lilly medications on Hims & Hers' platform, and the related customer response; Hims & Hers' ability to perform under and maintain the agreement with Lilly, including with respect to pricing, fulfillment, and Hims & Hers' commitments; and changes in the application, interpretation, and enforcement of healthcare, pharmacy, telehealth, consumer protection, or privacy laws or regulations applicable to our business, including those relating to prescription .

这些风险和不确定性包括但不限于：与礼来药品在 Hims & Hers 平台上的整合和推出相关的时机及物流考量，以及由此产生的客户反应；Hims & Hers 履行并维持与礼来协议的能力，包括在定价、履约以及 Hims & Hers 承诺方面的表现；以及适用于我们业务的医疗保健、药房、远程医疗、消费者保护或隐私法律或法规（包括与处方药相关的法规）在适用、解释和执行方面的变化。

GLP-1

胰高血糖素样肽-1

medications; and other factors described in the Risk Factors and other sections of Hims & Hers' most recently filed Quarterly Report on Form 10-Q, Hims & Hers' most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission..

药物；以及Hims & Hers最近提交的10-Q表格季度报告、Hims & Hers最近提交的10-K表格年度报告，以及我们不时向美国证券交易委员会提交的其他当前和定期报告中“风险因素”及其他章节所述的其他因素。

Should one or more of these risks or uncertainties materialize, or should any of Hims & Hers' assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of November 6, 2026.

如果上述风险或不确定性中的一项或多项成为现实，或者 Hims & Hers 的任何假设被证明不正确，实际结果可能会在这些前瞻性陈述所预测的内容上存在重大差异。本通讯中的前瞻性陈述仅截至 2026 年 11 月 6 日作出。

We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

我们不承担任何更新或修订任何前瞻性陈述的义务（并明确否认任何此类义务），也不承担更新可能导致实际结果与前瞻性陈述中预期存在重大差异的原因的义务，无论是否因新信息、未来事件或其他原因所致，除非适用法律另有要求。

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that Hims & Hers' actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication..

前瞻性陈述因其性质而涉及风险和不确定性，因为它们涉及未来可能发生也可能不发生的事件，并取决于未来可能出现也可能不出现的情况。我们提醒您，前瞻性陈述并非对未来表现的保证，Hims & Hers 的实际结果可能与本沟通中所包含的前瞻性陈述中作出或暗示的结果存在重大差异。

Refer to:

参见：

Michael Jamison;

迈克尔·贾米森；

Michael.Jamison@lilly.com

(Lilly Media)

（礼来媒体）

Michael Czapar;

迈克尔·查帕尔；

czapar_michael_c@lilly.com

(Lilly Investors)